Merck and Eisai got an accelerated okay from the FDA for the combination of PD-1 inhibitor Keytruda (pembrolizumab) with Eisai’s targeted therapy Lenvima (lenvatinib) in September 2019 based on ...

Keytruda, meanwhile, was greenlit by the FDA in patients with MSI-H or dMMR mutations last year, and is also approved in a combination regimen alongside Eisai’s Lenvima (lenvatinib) in ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...